COVID-19 VACCINE BNT162b2 entered Phase II / III clinical studies.

Pfizer and its partner BioNTech said recently that they have decided to move the nucleoside-modified mRNA vaccine candidate BNT162b2 into Phase II/III clinical trials.
BNT162b1 encoded optimized SARS-CoV-2 receptor binding domain (RBD) antigen.
expects the trial to recruit 30,000 participants between the ages of 18 and 85 who will be randomly assigned to BNT162b2 or placebo treatment in the United States and countries such as Argentina, Brazil and Germany.
BNT162b2 is part of the BNT162 mRNA vaccine program. earlier this
month, Pfizer and BioNTech announced the results of an ongoing Phase I/II study from the United States and Germany that showed bnT162b1 can stimulate anti-SARS-CoV-2 immunity in healthy volunteers.
BNT162b2 induces "high-intensity" CD4 plus and CD8 plus T cell reactions. "BnT162b2 can be the primary candidate based on all available data from our preclinical and clinical studies, including immune response and tolerance parameters," the
said.
.